Business
Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer
TSX Venture: QPT EDMONTON , June 9, 2014 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Q...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\nTSX Venture: QPT\n\n\n\nEDMONTON, June 9, 2014 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) (\"Quest\" or the \"Company\"), a pharmaceutical company developing and commercializing products for the treatment of cancer, reports today that patient enrollment has been completed in the Company's Phase IIb clinical trial of its lead immunotherapy product candidate Oregovomab for the treatment of Ovarian Cancer.\n\n\"I am pleased that we have reached this important milestone in our clinical program\" said Dr. Madi Madiyalakan, CEO of Quest.  \"I would like to thank everyone involved in the trial that helped to realize this significant Company objective.\"\n\nThis clinical study is the first of three clinical trials that the Company is conducting for its lead immunotherapy product Oregovomab in conjunction with preclinical studies dissecting combinatorial immunotherapy. It is a Phase IIb study with 80 patients for assessing the safety and bioactivity of combination chemo-immunotherapy of advanced ovarian cancer using standard front line carboplatin paclitaxel chemotherapy in combination with the anti-CA125 antibody Oregovomab relative to chemotherapy alone.  Thirteen clinical centers in Italy and the U.S are participating in the study with Professor Angioli at University Campus Bio Medico in Rome, Italy as the principal investigator. The objective of this study is to confirm the specific immune response seen in the combination front line setting (Braly 2009) in a population with more favorable surgical debulking. The enrolled patients will complete the treatment schedule and be followed up for long term disease outcomes. Immunology data for all patients who completed the treatment phase will be analyzed and evaluated while the final survival data is being collected.\n\n\"Quest is focusing on combination strategies to improve the demonstrated power of the immune system to control cancer\", commented Dr. Christopher Nicodemus, M.D. FACP, Chairman of the Company's clinical advisory board. \"Recent advances with checkpoint blockade have revolutionized this field, and antibody directed stimulation of specific immunity in conjunction with newly established approaches has the potential to raise the bar still higher\".\n\nThe Company is also  studying Oregovomab clinically in combination with chemotherapy and radiotherapy in CA...